HONG KONG SAR - Media OutReach Newswire - 19 May 2026 - Amplexd Therapeutics, Inc. ("Amplexd"), a U.S.-based clinical-stage biotechnology company focused on women's health and underserved therapeutic areas, today announced authorization from the Hong Kong Department of Health to initiate a Phase 2 clinical trial evaluating its novel EGCg-based investigational therapy for precancerous cervical lesions associated with high-risk human papillomavirus (hr-HPV).